β阻滞剂具有临床上有用的降压、抗心绞痛和抗心律失常性质,这一发现已经引起了临床、研究人员以及药学界的兴趣。此外,在多种次要性质方面的一些小差别导致猜测一些特殊种类的药物可能比其他种类有其优点。最初的小规模试验显示β阻滞剂降低心肌梗塞后的死亡率,从这些喜人的报告而来的热心吸引了为估计不同β阻滞剂在此场合所需的商业支持。此后可得到作为研究的β阻滞剂的增多使大规模临床试验的设计和执行都有相当的改善。尽管各种试验的结果有明显的差异,荟萃分析指出,若非全部,也是 Beta blockers have clinically useful antihypertensive, antianginal and antiarrhythmic properties, a finding that has drawn the interest of clinicians, researchers, and the pharmaceutical community. In addition, some minor differences in multiple secondary properties led to speculation that some special classes of drugs may have advantages over others. The first small-scale trials of beta blockers to reduce post-MI mortality have drawn enthusiastic reports from these gratifying reports of the commercial support needed to evaluate the different beta blockers in this setting. Subsequent availability of beta blockers as a study has resulted in considerable improvements in the design and implementation of large-scale clinical trials. Although there are significant differences in the results of various trials, meta-analyzes indicate that if not all,